Trial Profile

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sapanisertib (Primary)
Indications Merkel cell carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

03 Dec 2020 Status changed from active, no longer recruiting to completed.
09 Jan 2019 Planned End Date changed from 1 Jul 2020 to 1 Sep 2020.
09 Jan 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Sep 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com